Alpharadin Articles

Articles

An overview of current and emerging therapeutic management strategies for patients with metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Joelle El-Amm, MD and Jeanny Aragon-Ching, MD

BERKELEY, CA (UroToday.com) - The treatment of metastatic castrate resistant prostate cancer (mCRPC) has changed drastically over the past few years with the emergence of several new therapies.
Published July 12, 2013
Radium-223 chloride (Alpharadin) in patients with bone metastases and castration-resistant prostate cancer (CRPC): A new treatment paradigm - Video lecture by A. Oliver Sartor, MD

Listen to Dr. Sartor from Tulane University present new data from the phase III ALSYMPCA trial (ALpharadin in SYMptomatic Prostate CAncer) in this podcast: "Radium-223 Chloride (Alpharadin) in Patients With Bone Metastases and Castration-Resistant Prostate Cancer (CRPC): A New Treatment Paradigm"

Published July 29, 2013
Radium-223:The Only Approved Targeted Alpha Therapy (TAT) in mCRPC- Outcomes, Opportunities and Lessons Learned

Published in Everyday Urology - Oncology Insights: Volume 2, Issue 1
Published Date: March 2017

More than 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases which leads to a significant increase in morbidity and mortality.^1,2 Patients with metastatic prostate cancer and bone involvement have only a 3% five-year survival, whereas the five-year survival of patients without bone metastases is 56%.
Published June 9, 2017

Alpharadin Articles

Articles

An overview of current and emerging therapeutic management strategies for patients with metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Joelle El-Amm, MD and Jeanny Aragon-Ching, MD

Radium-223 chloride (Alpharadin) in patients with bone metastases and castration-resistant prostate cancer (CRPC): A new treatment paradigm - Video lecture by A. Oliver Sartor, MD

Radium-223:The Only Approved Targeted Alpha Therapy (TAT) in mCRPC- Outcomes, Opportunities and Lessons Learned

Login